JPMorgan Chase & Co. increased its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) by 101.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,144 shares of the biotechnology company’s stock after purchasing an additional 19,735 shares during the period. JPMorgan Chase & Co. owned 0.07% of Astria Therapeutics worth $431,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in the business. Quest Partners LLC grew its holdings in Astria Therapeutics by 180.8% in the third quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,798 shares during the period. PDT Partners LLC acquired a new stake in Astria Therapeutics during the 3rd quarter worth approximately $140,000. SG Americas Securities LLC purchased a new position in Astria Therapeutics in the third quarter valued at approximately $155,000. Hsbc Holdings PLC purchased a new stake in Astria Therapeutics during the second quarter worth approximately $171,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Astria Therapeutics in the third quarter worth $228,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.
Astria Therapeutics Stock Performance
Shares of ATXS opened at $7.49 on Wednesday. Astria Therapeutics, Inc. has a one year low of $7.16 and a one year high of $16.90. The stock has a 50-day moving average price of $9.05 and a 200 day moving average price of $10.52. The company has a market capitalization of $422.66 million, a P/E ratio of -3.58 and a beta of 0.70.
Analyst Ratings Changes
Get Our Latest Stock Report on ATXS
Astria Therapeutics Company Profile
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Featured Stories
- Five stocks we like better than Astria Therapeutics
- How to Calculate Options Profits
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- EV Stocks and How to Profit from Them
- What Does the Future Hold for Eli Lilly?
- Investing in the High PE Growth Stocks
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.